Skip to content
Open access

Preclinical identification of an oxadiazole-pyrazole lead targeting prostate cancer through integrated mechanistic evaluation

Sep 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 32 references
Medicine

TL;DR

VS-04 was identified as a promising oxadiazole–pyrazole lead with potent antiproliferative activity against prostate cancer cells, which was associated with AR modulation, oxidative stress, cell-cycle perturbation, and apoptotic cell death.

Abstract

Background Prostate cancer remains a major cause of cancer-related mortality among men, while resistance to androgen deprivation therapy emphasizes the need for new therapeutic strategies. Molecular hybridization of pharmacologically relevant heterocycles offers a rational approach for developing novel anticancer agents. Methods Twenty oxadiazole–pyrazole hybrids (VS-01–VS-20) were designed, synthesized, and evaluated using molecular docking against the androgen receptor (PDB ID: 1Z95), followed by in vitro antiproliferative assessment against androgen-dependent LNCaP and androgen-independent PC-3 prostate cancer cells. The lead compound was further investigated for its effects on androgen receptor expression, intracellular reactive oxygen species (ROS), cell-cycle progression, and apoptosis using flow cytometry and fluorescence microscopy. ADMET properties were additionally predicted computationally. Results VS-04 demonstrated a favorable interaction profile within the androgen receptor ligand-binding pocket and exhibited potent antiproliferative activity, with IC50 values of 394.95 ± 3.03 nM against PC-3 and 464.85 ± 4.29 nM against LNCaP cells. Docking–activity correlation analysis revealed a moderate and significant association between docking affinity and PC-3 antiproliferative activity, whereas no significant correlation was observed for LNCaP cells. VS-04 treatment produced a concentration-dependent reduction in androgen receptor expression and increased intracellular ROS levels. Mechanistic studies further demonstrated pronounced S-phase accumulation and induction of apoptosis, with the total apoptotic population increasing from 7.45% in control cells to 47.83% following VS-04 treatment. Conclusion The integrated computational and experimental evaluation identified VS-04 as a promising oxadiazole–pyrazole lead with potent antiproliferative activity against prostate cancer cells. Its activity was associated with AR modulation, oxidative stress, cell-cycle perturbation, and apoptotic cell death, supporting further structural optimization and preclinical investigation of this scaffold for prostate cancer therapy.

Read PDF

Similar papers

Sep 2026

Structure-based Drug Design and Pharmacokinetic Profiling of Novel Heterocyclic Androgen Receptor Inhibitors for Prostate Cancer Treatment

The utility of structure-based virtual screening combined with ADMET prediction as an effective strategy for early-stage lead identification in prostate cancer drug discovery and the improved predicted pharmacokinetic properties suggest that rational modification of heterocyclic scaffolds can yield AR antagonists with...

Vanktesh Kumar, Shivank Sharma, Saminesh Kumar et al. · 0 citations
Sep 2026

Design, synthesis, mechanistic evaluation, and in silico study of pyrimidine-coumarin hybrids as promising anticancer agents.

Breast and lung cancers remain among the leading causes of cancer-related mortality worldwide, highlighting the urgent need for the development of effective targeted therapeutics. In this study, a series of novel pyrimidine-coumarin hybrid derivatives were rationally designed, synthesized, and biologically evaluated fo...

R. Vinay, S. Alegaon, H. S. Basavaraja et al. · 0 citations
Review Aug 2026

Mechanism and Molecular Target of Substituted Triazoles: A Therapeutic Strategy in Anticancer Drug Discovery.

This review is an attempt to bridge the gap between synthetic structural biology and translational oncology by systematically connecting the structure- activity relationships of novel triazole hybrids targeting Aromatase, VEGFR-2, IDO1, and Carbonic Anhydrase.

Yashika Jangra, S. Dev, P. Jain · 0 citations
Open access Sep 2026

Quinoline clubbed triazole hybrids as VEGFR-2 targeted anticancer agents: synthesis, molecular modeling, and biological evaluation

Findings highlight quinoline–triazole hybrid SVI08 as a preliminary lead to the further optimization as a VEGFR-2-targeted anticancer agents as well as acceptable ADMET properties and good in vivo tolerability up to 50 mg/kg.

Divyanshi Thakur, Mangaldip Ghosh, Shivam Nag et al. · 0 citations
Review Open access Sep 2026

Molecular insights into triazole-based compounds for triple-negative breast cancer treatment

Abstract Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype lacking oestrogen, progesterone, and HER2 receptors, thus limiting the effectiveness of targeted therapies. Triazole compounds have emerged as promising anticancer agents because of their structural versatility, chemical stability, and...

Ahamed Vilangalil, S. S, Sarad Pawar Naik Bukke et al. · 0 citations

Design, synthesis and anti-proliferative evaluation of novel pyrazole-based ar-turmerone derivatives in colorectal cancer cells

The rational design and synthesis of eight newly developed pyrazole-based compounds derived from ar-turmerone aimed at enhancing COX-2 inhibition and antiproliferative activity against CRC highlight the potential of pyrazole-based ar-turmerone analogs as promising lead candidates for selective COX-2 inhibition and targ...

Monsin Sangsawat · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.